Analysts Set Charles River Laboratories International, Inc. (NYSE:CRL) Price Target at $214.38

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have earned a consensus rating of “Reduce” from the fifteen analysts that are presently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $214.38.

A number of research analysts have commented on the company. Barclays reduced their target price on Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating on the stock in a report on Thursday, August 8th. UBS Group raised their price objective on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Baird R W lowered shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 8th. Finally, Bank of America lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $250.00 to $215.00 in a research note on Wednesday, October 2nd.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Boston Trust Walden Corp raised its position in shares of Charles River Laboratories International by 2.8% in the second quarter. Boston Trust Walden Corp now owns 200,314 shares of the medical research company’s stock valued at $41,381,000 after purchasing an additional 5,375 shares during the period. Tidal Investments LLC lifted its position in Charles River Laboratories International by 99.8% during the 1st quarter. Tidal Investments LLC now owns 5,297 shares of the medical research company’s stock worth $1,435,000 after acquiring an additional 2,646 shares during the last quarter. Quest Partners LLC boosted its holdings in Charles River Laboratories International by 135,175.0% during the second quarter. Quest Partners LLC now owns 5,411 shares of the medical research company’s stock valued at $1,118,000 after acquiring an additional 5,407 shares during the period. New England Research & Management Inc. acquired a new stake in shares of Charles River Laboratories International in the second quarter valued at about $506,000. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Charles River Laboratories International by 3.4% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company’s stock worth $22,060,000 after purchasing an additional 3,714 shares during the period. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $199.06 on Friday. Charles River Laboratories International has a 52 week low of $176.48 and a 52 week high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The stock has a market cap of $10.18 billion, a P/E ratio of 24.91, a price-to-earnings-growth ratio of 5.15 and a beta of 1.38. The stock has a 50 day moving average of $194.32 and a 200-day moving average of $204.95.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.43 by $0.16. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period last year, the business earned $2.72 EPS. On average, analysts expect that Charles River Laboratories International will post 10.19 EPS for the current fiscal year.

Charles River Laboratories International declared that its Board of Directors has authorized a stock repurchase plan on Wednesday, August 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy up to 9.6% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).